RESUMEN
OBJECTIVE:To observe the clinical efficacy and safety of recombinant human interferon α2b (rhIFN α2b) combined with bozhi glycopeptides or thymopentin in the treatment of chronic hepatitis B (CHB).METHODS:Ninety HBeAg-positive CHB patients were selected from our hospital during Jan.2014-Jan.2015 and then randomly divided into group A,B,C,with 30 cases in each group.Group A was given rhINF α2b for injection (Pseudomonas) 5 million IU subcutaneously,qod;group B was additionally given Bozhi glycopeptides injection 4 mL added into 5％ Glucose injection 250 mL,ivgtt,qd,on the basis of group A;group C was additionally given Thymopentin for injection 2 mg added into 5％ Glucose injection 250 mL,ivgtt,qd,on the basis of group A.Three groups were treated for 24 weeks.The rate of ALT recovering to normal,negative rate of HBeAg,transformation rate of HBeAg/anti-HBeAg serum,negative rate of HBV-DNA and the decrease of HBsAg and HBV-DNA were compared among 2 groups after 4,8,12,24 weeks of treatment.The occurrence of ADR was recorded.RESULTS:After 4,8,12 weeks of treatment,there was no statistical significance in the rate of ALT recovering to normal,negative rate of HBeAg,transformation rate of HBeAg and the decrease of HBsAg among 3 groups (P＞0.05).After 4 weeks,negative rate of HBV-DNA in group B,C were significantly higher than group A;the decrease of HBV-DNA in group C were more significant than group A and B,with statistical significance (P＜0.05).After 8,12 weeks of treatment,the negative rate of HBV-DNA and the decrease of HBV-DNA in group B,C were significantly higher than group A,with statistical significance (P＜0.05);but there was no statistical signifi cance between group B and C (P＞0.05).After 24 weeks of treatment,there was no statistical significance in the rate of ALT recovering to normal,transformation rate of HBeAg,the decrease of HBsAg and negative rate of HBsAg among 3 groups (P＞0.05).The negative rate of HBsAg,negative rate of HBV-DNA and the decrease of HBV-DNA in group B,C were significantly higher than group A,with statistical significance (P＜0.05);there was no statistical significance between group B and C (P＞0.05).There was no statistical significance in the incidence of ADR among 3 groups(P＞0.05).CONCLUSIONS:rhIFN α2bcombined with bozhi glycopeptides or thymopentin shows good inhibitory effect on CHB,therapeutic efficacies of them are similar in the rate of ALT recovering to normal,but transformation rate of HBeAg,the decrease of HBsAg and negative rate of HBeAg.
RESUMEN
Objective:To analyze the clinical application of Bozhi glycopeptides to provide reference for its rational use in clinics . Methods:The related literatures of Bozhi glycopeptides from the databases of CNKI , Wanfang and VIP were retrieved .The main clinical application ( the number of literatures on the same disease entities was above 3) and ADR were analyzed and evaluated .Results:A total of 163 literatures were found, including 137 clinical application and 11 ADR case reports.The disease with the number of literatures a-bove 3 included condyloma acuminatum (9 literatures), herpes zoster (6 literatures), hand-foot-mouth disease (6 literatures), psoriasis vulgaris (6 literatures), lung cancer (5 literatures), repeated respiratory infection (4 literatures) and hepatitis B (9 literatures), and the total number was 45.Among them, 32 literatures (1 772 cases) involved ADR, and 49 cases (2.77%) of ADR were reported, and the main performance was skin and its appendages damage (10 cases, 20.0%).Totally 11 ADR case reports mainly involved rigors and fever (13 cases, 37.2%).Conclusion:Bozhi glycopeptides as an adjuvant drug is mainly combined with other drugs to enhance the effi -cacy of mian drugs in clinical application , which shows low incidence of ADR mainly including skin and its appendages damage .